Needham lowered the firm’s price target on Glaukos (GKOS) to $115 from $176 “due to lower peer multiples” but keeps a Buy rating on the shares. The company’s Q1 revenue beat consensus, and while management reiterated its 2025 revenue guidance, the implied iDose contribution increased by about $5M, the analyst tells investors in a research note. iDose reimbursement continues to expand, which should drive further adoption, the firm adds.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos price target lowered to $135 from $140 at Truist
- Wells downgrades Glaukos with iDose growth priced in
- Glaukos downgraded to Equal Weight from Overweight at Wells Fargo
- Positive Buy Rating for Glaukos Amid Strong iDose Performance and Awaited FDA Decision
- Glaukos’s Promising Outlook: Buy Rating Amid Strong Sales and Strategic Growth Opportunities